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Abstract 63 
 64 
Objective: Epidemiological data suggest that low serum 25-hydroxyvitamin D3 (25-OH-D3) levels are 65 
associated with radiological progression of knee osteoarthritis (OA). This study aimed to assess 66 
whether vitamin D supplementation can slow the rate of progression. 67 
Method:  A 3 year, double-blind, randomised, placebo-controlled trial of 474 patients aged over 50 68 
with radiographically evident knee OA comparing 800 IU cholecalciferol daily with placebo. The 69 
primary outcome was rate of medial joint space narrowing (JSN) over three years. Secondary 70 
outcomes included lateral JSN, Kellgren and Lawrence grade, WOMAC pain, function, stiffness and 71 
the Get up and Go test. 72 
Results: Vitamin D supplementation increased 25-OH-D3  from an average of 20·7 (SD 8·9) μg/L to 73 
30·4 (SD  7·7) μg/L, compared to 20·7 (SD  8·1) μg/L and 20·3 (SD  8·1) μg/L in the placebo group. 74 
There was no significant difference in the rate of JSN over three years in the medial compartment of 75 
the index knee between the treatment group (average -0.01 mm/year) and placebo group (-0.08 76 
mm/year), average difference 0.08 mm/year, (95% CI [ -0·14 to 0·29], p=0.49).  No significant 77 
interaction was found between baseline vitamin D levels and treatment effect.  There were no 78 
significant differences for any of the secondary outcome measures. 79 
Conclusion: There is no clear evidence that vitamin D supplementation slowed the rate of JSN or led 80 
to reduced pain, stiffness or functional loss over a three year period. On the basis of these findings 81 
we consider that vitamin D supplementation has no role in the management of knee OA. 82 
 83 
Abstract word count: 248/250 84 
 85 
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Introduction 87 
 88 
Knee Osteoarthritis (OA) is a chronic, painful disease associated with considerable morbidity, costs 89 
and disability 1. In the U.S., it is estimated that over a third of people aged over 60 have radiographic 90 
knee OA2 and over 50% of these with knee OA will go on to have a total knee replacement in their 91 
lifetime3.  At present there are no licensed treatments that alter disease progress and management is 92 
primarily concerned with symptom control to retain or improve joint function. 93 
 94 
Vitamin D deficiency (defined as 25-hydroxyvitamin D3(25-OH-D3) serum levels below 20μg/mL 
4 5) is 95 
common in the UK with estimates of over 12% for people living in private households and 30% of 96 
care home residents in the over 65s. There has been considerable interest in the association 97 
between vitamin D deficiency and OA incidence and progression. Vitamin D has a number of 98 
important biological functions in bone, cartilage and muscle6 which has led to the hypothesis that 99 
vitamin D supplementation may prevent the progression of OA. There is evidence from a number of, 100 
but not all, epidemiological studies suggesting that low dietary intake of vitamin D and low serum 25-101 
OH-D3 levels are associated with increased radiological progression of knee OA 
7-13. Epidemiological 102 
data from the Framingham Study demonstrated that low vitamin D intake was associated with a 103 
three to four-fold increased risk of radiographic progression at two skeletal sites over 8-10 years.7 104 
Further analysis of a separate cohort of patients in the Framingham study, along with another cohort 105 
from the Boston Osteoarthritis of the Knee Study (BOKS) found no association between vitamin D 106 
status and joint space or cartilage loss in knee OA 12. 107 
 108 
Findings from RCTs have thus far not conclusively settled this debate 14-17. A 12 month trial of vitamin 109 
D in 107 vitamin D insufficient subjects with knee OA found a small but statistically significant 110 
improvement in pain 14.  A trial of 146 subjects with symptomatic knee OA found that vitamin D 111 
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supplementation for two years had no effect on the structural progression of OA using MRI as the 112 
primary outcome 16. A further post hoc analysis of a RCT concluded that calcium plus vitamin D 113 
supplementation for two years in post-menopausal women had no effect on self-reported frequency 114 
or severity of joint symptoms 17. As these trials were heterogeneous in terms of patients recruited, 115 
sample sizes and some also used calcium in addition to vitamin D supplements, it is important to 116 
have a large RCT with a prolonged follow up to provide further clarity on the role of vitamin 117 
supplementation in patients with knee OA. 118 
 119 
Aim 120 
 121 
The primary aim of this trial was to determine whether vitamin D supplementation can reduce the 122 
rate of structural progression of knee OA as measured by change in medial joint space assessed on a 123 
weight-bearing radiograph over a 3-year period. Secondary outcomes included changes in pain and 124 
function. 125 
 126 
Methods 127 
 128 
Study design 129 
 130 
The VIDEO study was a double-blind, randomised, placebo-controlled trial performed at five UK NHS 131 
hospitals. Participants were randomly assigned to receive either 800IU of oral cholecalciferol or 132 
matched placebo daily. Data from clinical trials indicated that 800IU/day of cholecalciferol can 133 
produce significant increases in serum 25-hydroxyvitamin D3 levels and that these increases are 134 
evident within one month of starting treatment18.  The protocol was approved by the Scotland A 135 
Research Ethics Committee and the trial was registered with EudraCT: ref. 2004-000169-37, 136 
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ISRCTN94818153, CTA No. 11287/0001/001. The trial was conducted in accordance with Good 137 
Clinical Practice guidelines and the Declaration of Helsinki. 138 
 139 
Participants were identified from GP lists, patient referrals to hospitals and via radio advertisements. 140 
Patients were eligible if they: were aged >50 years, ambulatory, had radiological evidence of knee 141 
OA at medial tibio-femoral knee compartment (Modified Kellgren & Lawrence (K&L) score 2/3, JSW 142 
>1mm) and knee pain for most days of the previous month. Reasons for exclusion were: secondary 143 
OA, inflammatory arthritis, early morning knee stiffness for >30 minutes, cod liver oil or vitamin 144 
supplementation containing vitamin D >200 IU, glucosamine or chondroitin use for <three months, 145 
osteoporotic fracture, previous knee surgery or arthroscopy within six months, use of 146 
bisphosphonates within two years. Eligible participants were invited to a screening appointment. 147 
Informed consent was taken along with knee radiographs, which were assessed by the local clinician 148 
to determine eligibility. 149 
 150 
Randomisation and blinding 151 
 152 
Eligible participants were randomised centrally by the UK Medical Research Council Clinical Trials 153 
Unit (MRC CTU) via telephone to receive either oral vitamin D or matching placebo tablets (1:1) by 154 
computer-generated randomisation with stratification by recruitment centre. Treatment allocation 155 
was concealed from the patients, clinicians, outcome assessors and investigators. Both the active 156 
treatment and placebo were manufactured by Thompson and Capper Ltd, and packed by Bilcare 157 
Global Clinical Supplies (Europe) Ltd. 158 
 159 
8 
 
Trial procedures 160 
 161 
At the baseline visit knee bilateral radiographs and blood samples were taken, and the assigned drug 162 
dispensed in six month packs. Radiographs and blood sampling were repeated at 12 months and 36 163 
months. Questionnaires (WOMAC) were completed at 6-monthly intervals until the final visit. Blood 164 
was drawn to measure serum 25-OH-D3 at baseline and 12 months to assess baseline vitamin D 165 
status and response to supplementation. Serum vitamin D2 and D3 concentrations were assayed at 166 
King’s College Hospitals NHS Foundation Trust via mass spectrophotometry using the MassChrom 167 
reagent kit (Chromsystems Instruments & Chemicals GmbH).  168 
 169 
Outcome measures 170 
 171 
The primary outcome measure was radiological progression of knee OA in the medial joint 172 
compartment of the index knee (knee with the smallest joint space width (JSW) at baseline in the 173 
case of bilateral disease), as measured by the rate of JSN (mm/year) over the three years. Knee X-174 
rays were taken using the MTP technique 19 using a foot map to improve accurate re-positioning at 175 
follow up visits.  176 
All joint space measurements were performed by a single reader. Reproducibility was excellent, and 177 
comparable to previous results using the same software package 20, 21; intra-rater intra-class 178 
correlation coefficients (ICCs) were: 0·96 medial 95% CI [0·88-0·98], 0·98 lateral 95% CI [0·94 0·99].  179 
Secondary outcomes measures included: rates of change in minimum JSW of the lateral 180 
compartment, and of the medial and lateral compartments of the contralateral knee, Kellgren and 181 
Lawrence (K&L)22, 23 grade, WOMAC VAS scores (0-100 pain, stiffness, function and total) in the index 182 
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knee, and Get up and Go test. Baseline and follow-up X-rays were graded for K&L grade by a Clinical 183 
Orthopaedic Fellow, with an intra-reader Kappa of 0·68.  184 
 185 
Sample size 186 
 187 
The study was designed to detect a clinically important mean difference of 0·22mm/year in the rate 188 
of JSN between treatment groups over three years, assuming a standard deviation of 0·7 mm 24, 25, 189 
with 80% power at the 5% significance level. Allowing for 32% drop-out rate, the total sample size 190 
required was 470. 191 
 192 
Statistics 193 
 194 
Analysis was conducted following the intention-to-treat principle and in accordance with a pre-195 
specified analysis plan which was finalised prior to database lock and breaking the blind.  196 
To assess JSN a longitudinal analysis was performed using a linear mixed regression model with fixed 197 
effects for treatment, time, treatment by time and adjustment for: baseline JSW, centre, gender, 198 
glucosamine or chondroitin use, age and BMI. To allow for between patient differences the model 199 
included a random patient intercept. The central parameter of interest was the treatment by time 200 
interaction, which represents the average difference in the rate of JSN/year between the treatment 201 
groups. Continuous secondary outcomes were analysed similarly. Changes in ordinal outcomes over 202 
time were analysed using ordinal logistic regression models with robust Huber-White sandwich 203 
estimators of standard errors. The effect of treatment on the proportion of patients with clinically 204 
significant progression (JSN>0·5mm in the index knee) at three years was obtained using a Poisson 205 
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regression model with robust error estimates. For patients who had a total knee replacement (TKR) 206 
in the index knee during the trial, clinically significant progression was assumed. 207 
Mean imputation was used to deal with missing covariate values 26. For patients who had TKR during 208 
the trial, data before surgery was included and data after surgery assumed to be missing.  All missing 209 
outcome values were assumed to be missing at random and multiple imputation by chained 210 
equations was used 27, 28. Sensitivity analyses, including analysis of the complete cases and a range of 211 
missing not at random mechanisms, were performed to assess the robustness of the primary results 212 
to the effect of missing data (for full details see supplementary file eTable 2 and eFigure 1). All 213 
statistical analyses were performed using Stata/IC version 12·1 (StataCorp, College Station, TC, USA). 214 
 215 
Results 216 
 217 
In total, 474 participants were recruited between 19/01/2005 and 13/06/2008. Table 1 shows 218 
baseline clinical data and baseline radiographic characteristics. Additional baseline variables can be 219 
found in the supplementary file, eTable 1. The treatment and placebo groups were well matched for 220 
clinical characteristics and showed a similar distribution of radiographic characteristics. The 221 
distribution of serum 25-OH-D3, divided into tertiles (table 3), was almost identical in the two 222 
groups, with 50% of both groups vitamin D3 deficient (<20μg/L).  223 
As shown in Figure 1, 198 of participants in the placebo group (84%) and 188 of those in the 224 
treatment group (79%) attended the 3-year follow-up visit. Six patients in the placebo group and 225 
seven in the vitamin D group received a TKR of the index knee during the follow up period. Due to a 226 
combination of technical and logistic reasons, including poor positioning and quality a number of 227 
radiographs from attending patients, including baseline, could not be evaluated for JSW accurately.  228 
JSW in the medial compartment of the index knee was missing for a total of 37/474 patients (8%) at 229 
11 
 
baseline (18/237 placebo, versus 19/237 active), 110/474 patients (23%) at year one (58/237 230 
placebo versus 52/237 active) and 183/474 (39%) at year three (87/237 placebo versus, 96/237 231 
active). 38% of the missingness at year one (42/110) was due to unreadable X-rays (23 placebo and 232 
19 active). 30% of the missingness at year three (55/183) was due to unreadable X-rays (27 placebo 233 
versus 28 vitamin D).  The remaining missingness at year three occurred due to withdrawal 54% 234 
(99/183, 49 placebo (3 with TKR of index knee at one year) and 50 active (1 with TKR of index knee at 235 
one year)), loss to follow-up 10% (18/183, 7 placebo and 11 active), TKR of the index knee 5% 236 
(9/183, 3 placebo and 6 active) or death 1% (2/183, 1 placebo and 1 active).  Missingness of X-ray 237 
data did not vary by treatment arm. 380/474 patients (189/237 placebo, 191/237 active) had 238 
baseline and at least one follow up JSW reading available and were analysed separately as a 239 
sensitivity analysis. A separate analysis of the 242/474 patients (125/237 placebo, 117/237 active) 240 
with complete follow-up was also performed along with additional sensitivity analysis to assess the 241 
impact of missing data (supplementary file eTable 2 and eFigure 1). 242 
 243 
Vitamin D analysis 244 
 245 
At 12 months, serum vitamin D3 levels had increased from an average of 20·7 (8·9) μg/L at baseline 246 
to 30·4 (7·7) μg/L in the vitamin D group. Levels decreased for those receiving placebo from 20·7 247 
(8·1) μg/L at baseline to 20·3 (8·1) μg/L at 12 months (table 3). The number of patients with vitamin 248 
D deficiency (<20 g/L) fell to 7% in the vitamin D group but rose to 54% in the placebo group.  249 
 250 
 251 
Radiographic results  252 
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 253 
There was no significant difference in the rate of JSN over three years in the medial compartment of 254 
the index knee between treatment groups (-0.01mm/year versus -0.08mm/year for vitamin D and 255 
placebo respectively), between group difference 0·08 mm/year, 95% CI [-0·14 to 0·29], p=0·49 256 
(figure 2, table 2). Sensitivity analyses conducted to assess the effect of missing values on the 257 
estimated treatment effect produced results no different from the primary analysis (supplementary 258 
file eTable 2 and eFigure 1).  No interaction between baseline vitamin D status and treatment effect 259 
() was found (<20 µg/L,  0·06, 95% CI [-0·20 to 0·32]; 20 µg/L to 30 µg/L,  0·05, 95% CI [-0·20 to 260 
0·29]; >30 µg/L,  0·05, 95% CI [-0·30 to 0·40]) (Figure 3). 261 
There was no difference in the proportion of patients with clinically significant progression of JSN 262 
(JSN>0.5mm in the index knee) at three years between the vitamin D group (39%) and placebo group 263 
(37%). The absolute risk difference was 2% (95% CI [-10% to 14%], p = 0.76) (eTable 4).  264 
We explored the hypothesis that there may be an interaction between treatment effect and baseline 265 
JSN. The interaction did not reach significance (p=0·86, N = 474).  266 
 267 
Secondary outcomes 268 
 269 
The placebo group showed an increase in WOMAC pain whereas the vitamin D group showed a small 270 
decrease (0.71 versus -0.08 per year, between group difference -0.79, 95% CI [-2.31 to 0.74], table 2, 271 
eFigure 2). WOMAC stiffness decreased in both groups (-2·02 versus -0.50 per year for vitamin D and 272 
placebo groups respectively, between group difference -1.52, 95% CI [-3.24 to 0.21]). WOMAC 273 
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function increased for both groups (0.42 versus 1.07 per year for vitamin D and placebo, between 274 
group difference -0·65, 95% CI [-2·09 to 0·79]) . None of the above differences achieved statistical 275 
significance.  276 
Odds ratios of a higher K&L grade per year were calculated as 1.32 (Vitamin D) and 1.23 (placebo) for 277 
the index knee and 1.19 (Vitamin D) and 1.18 (placebo) for the contralateral knee. This gave a 278 
treatment by time odds ratio, which represents the increase in odds of a higher K&L grade per year 279 
for vitamin D patients relative to placebo, of 1.07 (95% CI [0.88 to 1.31]) for the index knee and 1.01 280 
(95% CI [0.80 to 1.27]) for the contralateral knee (table 2).  The odds of a higher get up and go test 281 
grade per year for Vitamin D patients was 1.00 and 1.04 for placebo patients. There was no 282 
significant difference in the odds of a higher get up and go test grade over time between the 283 
treatment groups (OR = 0.96, 95% CI [0.73 to 1.27]). Additional secondary outcomes were assessed 284 
and treatment effect estimates can be found in the supplementary file eTable 4. All outcomes at 285 
three years are summarised in eTable 5.  286 
 287 
 288 
Adverse events 289 
 290 
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There was no difference in the proportion of patients experiencing SAE’s between the vitamin D 291 
(59/237, 25%) and placebo group (64/237, 27%), p = 0.67 or in the rates of occurrence of 292 
hypercalcaemia (five placebo, three vitamin D) or hypercalciuria (34 placebo, 46 vitamin D). 293 
 294 
Discussion 295 
 296 
There is no clear evidence that vitamin D supplementation, at a dose of 800 IU cholecalciferol daily, 297 
had an effect on the progression of knee OA over the three year period, as measured by changes in 298 
JSW, or on knee pain, function or stiffness. This is despite the fact that participants had high rates of 299 
vitamin D deficiency at trial entry, and the level of supplementation was sufficient to increase serum 300 
vitamin D levels by 10 μg/L on average in the first year of treatment, reducing the proportion of 301 
participants with deficiency by over 80%.  302 
Previous research has not provided a consensus on the effect of vitamin D on the progression of 303 
knee OA, with observational studies and RCTs generating conflicting findings. Several high quality 304 
epidemiologic studies have demonstrated an association between low serum vitamin D and /or 305 
vitamin D intake and the risk of either OA incidence or progression 8-11, however others have shown 306 
no association 12, 13, 15, 29-31. These studies vary in methodology and were also subject to a number of 307 
important biases.   308 
McAlindon performed a two year RCT of 2000 IU/day oral cholecalciferol for patients with 309 
symptomatic knee OA. The primary outcomes were cartilage volume loss measured by MRI and knee 310 
pain by WOMAC.  The population studied had similar baseline concentrations of vitamin D but 311 
greater baseline JSW (approximately 5mm vs. 3.5mm).  The results demonstrated that despite 61.3% 312 
of patients achieving target concentrations of vitamin D, there were no significant improvements 313 
over placebo in any of the outcomes. Sanghi et al performed a 12 month RCT of vitamin D 314 
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supplementation in patients with knee OA and vitamin D deficiency 15. They demonstrated a 315 
statistically significant reduction in pain and increase in physical function in a group taking vitamin D 316 
compared with placebo, however the difference between the two groups was not deemed to be 317 
clinically important 32.  318 
The results from our study, which is substantially larger than the previous studies, are consistent 319 
with the above results. The VIDEO trial contributes several new findings. Firstly, we measured JSN 320 
and K&L grade in the contra-lateral knee.  This is important as pathogenic mechanisms may be 321 
different in the contra-lateral joint compared with the index knee which exhibits later stage disease 322 
in patients with bilateral OA, as suggested in the Doxycycline trial by Brandt et al 25. In addition, we 323 
measured JSN in the medial and lateral compartments individually. Although medial compartment 324 
disease is far more prevalent, and the majority of previous studies focus only on joint space changes 325 
in the medial compartment 4, 25, it is important to measure JSN in the lateral compartment to ensure 326 
disease progression is not missed 33. We looked at the association of the treatment effect with 327 
baseline [25-OH-D3] concentration and the change in vitamin D concentration after 12 months of 328 
treatment. This study has a longer follow-up period than previous trials, with three year JSN having 329 
been shown in a previous study to be predictive of the incidence of osteoarthritis related knee 330 
surgery 34.  331 
 332 
Strengths and potential limitations 333 
 334 
A key strength of VIDEO was the inclusion of patients who were not biochemically vitamin D 335 
deficient. Laslett et al found that vitamin D deficiency was associated with incident or worsening of 336 
knee pain over a five year period 35, suggesting that vitamin D supplementation would be effective in 337 
attenuating the progression of knee pain only in those who already show moderate deficiency. 338 
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However, 50% of VIDEO participants had vitamin D insufficiency (<20 μg/L) at baseline. When 339 
analysis of treatment effect on JSN was broken down by baseline vitamin D status, no significant 340 
interactions with the treatment effect were found. Vitamin D supplementation had no effect on the 341 
change in joint space width even in subjects who were vitamin D deficient. 342 
We acknowledge limitations. The radiographs from the screening visits were read by the local PI at 343 
each centre to establish eligibility into the trial. A clinical orthopaedic fellow re-read all the baseline 344 
x-rays for the final analysis. This explains why a proportion of the baseline radiographs were 345 
determined to be K&L grade 1, while the inclusion criteria specified K&L ≥2. The difference between 346 
the definitions of the two grades relates to a possible vs. definite osteophyte, this boundary being 347 
particularly subjective. The distribution however was similar between the two groups and would be 348 
unlikely to bias the results of the trial. Of interest, it allowed us to assess the effect of vitamin D in 349 
very early OA.  350 
The proportion of participants lost to follow-up by the three year visit (16% placebo group, 21% 351 
treatment group) could be considered a limiting factor. This rate of loss is consistent with other OA 352 
trials 4, 17, 25, 36and the sample size calculation allowed for 32% loss to follow up. An additional 353 
number of x-rays were unevaluable for JSW due to technical and logistic reasons. However, there 354 
was no evidence of a differential loss to follow up or unevaluable X-rays between treatment arms 355 
and detailed sensitivity analyses to assess the impact of missing data (described in supplementary 356 
file) were consistent with the primary analysis.  357 
 358 
Conclusions 359 
 360 
There is no clear evidence that vitamin D supplementation, at a dose sufficient to elevate serum 361 
vitamin D3 levels by 10 μg/L in one year, slowed the rate of JSN or led to reduced pain, stiffness or 362 
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functional loss over a three year period, when compared with placebo. On the basis of these findings 363 
we consider that vitamin D supplementation has no role in the management of knee OA. 364 
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Figure Legends 554 
 555 
Figure 1. Consort flow diagram for the VIDEO study  556 
Figure 2. Mean Joint Space Width in the medial compartment of the index knee with 95% CI’s by 557 
treatment group (N = 474). All available readings were included in primary analysis and multiple 558 
imputation was used to impute missing values, assuming all missing outcome values were missing at 559 
random, conditional on treatment and the covariates included in the imputation model. Both centre 560 
and baseline BMI were included in the imputation model.  561 
Figure 3. Scatterplot of baseline Vitamin D3 against three year change in Joint Space Width by 562 
treatment group with linear fit imposed (N = 463).  563 
 564 
 565 
 566 
 567 
 568 
 569 
24 
 
Table 1 Baseline Clinical and radiographic Characteristics as mean (sd) or number (%).  570 
 571 
 N vitamin D / 
 N Placebo 
Vitamin D 
 
Placebo  
Age (yrs) 237/237 64 (8) 64 (8) 
Sex: (% Female) 237/237 144 (61%) 145 (61%) 
Index knee: % Right 237/237 136 (57%) 146 (62%) 
BMI (kg/m2) 236/237 30 (5) 29 (5) 
Family history of knee or hip OA 236/235 113 (48%) 109 (46%) 
Heberdens nodes 237/237 145 (61%) 165 (70%) 
Bouchards nodes 237/237 71 (30%) 83 (35%) 
CMC joint OA 237/237 105 (44%) 101 (43%) 
% Bilateral knee OA 237/237 169 (71%) 166 (70%) 
% Taking analgesics 237/237 104 (44%) 98 (41%) 
% Taking glucosamine or 
chondroitin 
237/237 109 (46%) 104 (44%) 
% Taking cod liver oil 236/236 73 (31%) 78 (33%) 
WOMAC pain score  236/232  33 (18) 31 (19) 
WOMAC function score 236/232 36 (21) 35 (20) 
WOMAC stiffness score 236/231 47 (24) 43 (24) 
WOMAC total score 236/232 36 (19) 35 (19) 
    
Worst K&L grade+ (of 
medial/lateral) 
Index knee:                                    
234/236   
0  3 (1%) 3 (1%) 
1  62 (26%) 59 (25%) 
2  86 (37%) 92 (39%) 
25 
 
3  70 (30%) 66 (28%) 
4  13 (6%) 16 (7%) 
Worst K&L grade+ (of 
medial/lateral) 
Contra-lateral knee:          
   
0 234/236 2 (1%) 2 (1%) 
1  77 (33%) 87 (37%) 
2  65 (28%) 70 (30%) 
3  54 (23%) 43 (18%) 
4  29 (12%) 26 (11%) 
TKR Contra-lateral knee  7 (3%) 8 (3%) 
Medial JSW index knee (mm) † 218/219 3.49 (1.48) 3.58 (1.47) 
Lateral JSW index knee (mm) † 222/219 5.27 (1.95) 5.42 (1.87) 
Medial JSW Contra-lateral knee † 
(mm) 
214/213 3.40 (1.69) 3.62 (1.60) 
Lateral JSW Contra-lateral knee† 
(mm) 
216/212 5.38 (2.07) 
 
5.22 (1.90) 
Baseline Vitamin D3 (in µg/L)  20.7  (8.9) 20.7 (8.1) 
+Baseline X-rays were missing for 3 individuals in the vitamin D group. 1 placebo 572 
patients X-ray disc was corrupt therefore could not be read. Due to X-ray quality issues, 573 
including poor positioning, the numbers of readable JSW measures vary by region and by 574 
knee. 575 
 576 
 577 
 578 
 579 
 580 
 581 
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Table 2 Treatment effect estimates for primary and secondary outcomes 582 
 583 
Rate of change of Joint Space width 
(mm/year) 
Vitamin D  Placebo Difference [95% CI] 
Primary Outcome:    
Medial compartment index knee  -0.01  -0.08 0.08 [-0.14 to 0.29] 
Secondary Outcomes:    
Lateral compartment index knee  -0.11 -0.18 0.07 [-0.19 to 0.33] 
Medial compartment contra-lateral 
knee  
-0.03 0.03 -0.06 [-0.26 to 0.13] 
Lateral compartment contra-lateral 
knee  
-0.10 -0.07 -0.03 [-0.27 to 0.21] 
 Vitamin D  Placebo Difference [95% CI] 
Clinically significant progression   
(Medial index JSN>0.5mm)   
39%(N=92)  37%(N=88) 2% [-10% to 14%]1 
Rate of change per year Vitamin D  Placebo Difference [95% CI] 
WOMAC pain  -0.08 0.71 -0.79 [-2.31 to 0.74] 
WOMAC stiffness  -2.02 -0.50 -1.52 [-3.24 to 0.21] 
WOMAC function  0.42 1.07 -0.65 [-2.09 to 0.79] 
WOMAC total 0.11 0.84 -0.72 [-1.92 to 0.48] 
 Vitamin D 
 
Placebo  
 
Treatment x Time 
OR [95% CI] 
Odds of a higher K&L grade per year 
index knee 
1.32 1.23 1.07 [0.88 to 1.31] 
Odds of a higher K&L grade per year 
contra-lateral knee 
1.19 1.18 1.01 [0.80 to 1.27] 
Odds of higher grade in Get up and 1.00 1.04 0.96 [0.73 to 1.27] 
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go test per year 
N=474 (N=237 Vitamin D, N = 237 Placebo). WOMAC scores range from 0 to 100, 0 = no 584 
pain/disability, 100 = extreme pain/disability. Get up and Go test graded 1 - normal to 6 – abnormal. 585 
1Corresponds to a relative risk of 1.05 [0.77 to 1.44]. 586 
 587 
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Table 3 Vitamin D3 and Vitamin D2, at baseline and 12 months.  588 
 589 
 N vitamin D / 
 N Placebo 
Vitamin D  Placebo 
Baseline Vitamin D3: 232/231   
     <20 µg/L  117 (50%) 115 (50%) 
       20 µg/L  to 30 µg/L  79 (34%) 87 (38%) 
     >30 µg/L  36 (16%) 29 (12%) 
Baseline Vitamin D3 (in µg/L)  20.7  (8.9) 20.7 (8.1) 
    
Baseline Vitamin D2: 232/231   
     <2.2 µg/L  228 (98%) 218 (94%) 
     ≥2.2 µg/L  4 (2%) 13 (6%) 
Baseline Vitamin D2 (in µg/L)* 4/13 5.0 (2.7) 3.8 (1.7) 
    
12 month Vitamin D3:  206/206   
     <20 µg/L  14 (7%) 111 (54%) 
       20 µg/L  to 30 in µg/L  97 (47%) 67 (32%) 
     >30 µg/L  95 (46%) 28 (14%) 
12 month Vitamin D3 (in µg/L)  30.4 (7.7) 20.3 (8.1) 
    
12 month Vitamin D2: 206/206   
     <2.2 µg/L  203 (99%) 193 (94%) 
     ≥2.2 µg/L  3 (1%) 13 (6%) 
12 month Vitamin D2 (in µg/L)* 3/11 3.3 (0.76) 4.2 (2.3) 
29 
 
    
12 month change Vitamin D3 (µg/L) 201/201 9.4 (8.3) -0.8 (5.7) 
*Vitamin D2 reported in µg/L for patients with Vitamin D2 ≥2.2 µg/L only. Data presented as mean(sd) 590 
or number (%) for categorical variables. Vitamin D3 and Vitamin D2 were not available at baseline for 591 
5 vitamin D and 6 placebo patients and at 12 months for 31 vitamin D and 31 placebo patients,  for  592 
reasons unknown. 593 
 594 
 595 
 596 
 597 
 598 
 599 
 600 
 601 
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 602 
Figure 1. Consort flow diagram for the VIDEO study  603 
 604 
 605 
 606 
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 607 
Figure 2. Mean Joint Space Width in the medial compartment of the index knee with 95% CI’s by 608 
treatment group (N = 474 All available readings were included in primary analysis and multiple 609 
imputation was used to impute missing values, assuming all missing outcome values were missing at 610 
random, conditional on treatment and the covariates included in the imputation model. Both centre 611 
and baseline BMI were included in the imputation model.  612 
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 614 
Figure 3. Scatterplot of baseline Vitamin D3 against estimated three year change in Joint Space Width 615 
by treatment group with linear fit imposed (N = 463).  616 
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